|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-6-10
|
|
pubmed:abstractText |
In order to establish the safety of the Norwegian meningococcus B vaccine we have focused on detailed reporting of side effects in several phase II trials. We report here the results of the largest single phase II study, (step II-6) including 877 school children. The incidence of local side effects was significantly higher in the vaccine than in the placebo group, but most of them were mild and short-lasting. Mild systemic side effects were commonly reported in both groups, but more severe side effects were rare and almost equally distributed between the groups.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0332-5652
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
95-101; discussion 101-2
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:1812440-Adolescent,
pubmed-meshheading:1812440-Bacterial Capsules,
pubmed-meshheading:1812440-Bacterial Outer Membrane Proteins,
pubmed-meshheading:1812440-Bacterial Vaccines,
pubmed-meshheading:1812440-Double-Blind Method,
pubmed-meshheading:1812440-Fatigue,
pubmed-meshheading:1812440-Headache,
pubmed-meshheading:1812440-Humans,
pubmed-meshheading:1812440-Incidence,
pubmed-meshheading:1812440-Meningococcal Vaccines,
pubmed-meshheading:1812440-Norway,
pubmed-meshheading:1812440-Pain,
pubmed-meshheading:1812440-Polysaccharides, Bacterial,
pubmed-meshheading:1812440-Students
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.
|
|
pubmed:affiliation |
National Institute of Public Health, Oslo.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
